Pathology Quiz #18: Immune Checkpoint Interactions

1. A 55-year-old male with a history of melanoma is being treated with a novel therapeutic agent that enhances the immune response against tumor cells by blocking a specific receptor on T-cells. The mechanism of action of this agent is most likely related to inhibiting the interaction between which of the following pairs of molecules? 

Question 1 of 4

2. A research team is developing a new drug designed to inhibit the function of PD-1, a protein expressed on the surface of T-cells. The primary objective of this therapy is to: 

Question 2 of 4

3. A patient with advanced non-small cell lung cancer (NSCLC) is undergoing treatment with an immunotherapy agent that targets the interaction between a ligand on tumor cells and a receptor on T cells. This interaction normally leads to T-cell inactivity against tumor cells. The ligand-receptor pair most likely being targeted by this therapy is: 

Question 3 of 4

4. In a clinical trial for a solid tumor, a patient is receiving an immune checkpoint inhibitor therapy that targets an inhibitory receptor on T cells. The therapy aims to enhance anti-tumor immunity by lifting the inhibition on these cells. A potential adverse effect of this treatment is: 

Question 4 of 4


¡Por tiempo limitado!

Unete a nuestro boletín mensual y obtén todos nuestros talleres USMLE/ECFMG ¡GRATIS! (+100 videos)

¡Únete a nuestra comunidad de IMGs!

¡Obtén actualizaciones mensuales USMLE y ECFMG, además, obtén un taller USMLE gratis al instante!

"Taller 01: ¿Qué es el USMLE?”

Taller Gratuito USMLE

Este taller proporciona un análisis en profundidad de todos los exámenes USMLE, consejos para tomar exámenes y cómo estudiar de manera efectiva.


Especialista ECFMG: Dr. Carla Rebeca Lainez Casal

Facultad de Medicina: Universidad Catholica de Santiago de Guayaquil
ECFMG Certification date: October 13, 2022.
Residency: 2023 Internal Medicine Applicant
+1 7542724970